Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.0, a high estimate of $18.00, and a low estimate of $15.00. Observing a downward trend, the current average is 11.46% lower than the prior average price target of $19.20.

Deciphering Analyst Ratings: An In-Depth Analysis

A clear picture of NeoGenomics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NeoGenomics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on NeoGenomics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind NeoGenomics

Financial Milestones: NeoGenomics's Journey

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: NeoGenomics displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.57%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: NeoGenomics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -8.91%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): NeoGenomics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.69%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): NeoGenomics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.93%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: NeoGenomics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.